Not that long ago, interchangeability was seen as key to jumpstarting the biosimilar market in the U.S. Not so much anymore. As biosimilars continue to crawl onto the market, reality is setting in. Part of that reality is that the benefit interchangeability offers – automatic substitution at the pharmacy – only helps with biologic follow-ons dispensed at a pharmacy.